Evaluation the Effect of Montelukast as an adjunctive therapy on Treatment results (Proteinuria, Edema, Albumin Level) of Nephrotic Syndrome in Children

Evaluation the Effect of Montelukast as an adjunctive therapy on Nephrotic Syndrome in Children

This assessment is a clinical trial in Phase 3, children diagnosed with nephrotic syndrome that have been verified by pediatric specialist, are considered as study group. In this study, 40 children who meet the criteria are selected. Patients are categorized based on non randomization method, 20 children in the intervention group and 20 children in the control group. Accordingly, at the beginning of the diagnosis and 1 months after the start of treatment, the condition of the nephrotic syndrome is evaluated by signs and symptoms.

This study will be done as a clinical trial at the pediatric Clinic of Amir Kabir Hospital in Arak, Also the study will also be single blinded in which patients will be blinded in study.

Inclusion criteria is the only Nephrotic Syndrome, while patients who are not available during the next year to refer to the facility for follow-up or have other underlying conditions (such as hematology diseases or any other chronic disease), or intake drug for another illness, were excluded.

In intervention group, in addition to the usual treatment of nephrotic syndrome (corticosteroid), we also used vitamin D, in which Montelukast is administered as tables of 5 mg, in addition in control group we used the usual treatment for Nephrotic Syndrome is 60 mg / m2 / day is 60 mg of prednisolone (maximum dose of 80 mg / m2 / day) for 4-6 weeks, which is used in the control group.

Albumin level, Urinary tract infection, Edema

This means that patients in groups do not know the used drugs, and drugs has similar packaging.